249 related articles for article (PubMed ID: 21790156)
1. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases.
Cole KE; Dowling DP; Boone MA; Phillips AJ; Christianson DW
J Am Chem Soc; 2011 Aug; 133(32):12474-7. PubMed ID: 21790156
[TBL] [Abstract][Full Text] [Related]
2. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8.
Decroos C; Clausen DJ; Haines BE; Wiest O; Williams RM; Christianson DW
Biochemistry; 2015 Mar; 54(12):2126-35. PubMed ID: 25793284
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaplin A.
Zhang B; Shan G; Zheng Y; Yu X; Ruan ZW; Li Y; Lei X
Mar Drugs; 2019 Jun; 17(6):. PubMed ID: 31163697
[TBL] [Abstract][Full Text] [Related]
4. Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue.
Almaliti J; Al-Hamashi AA; Negmeldin AT; Hanigan CL; Perera L; Pflum MK; Casero RA; Tillekeratne LM
J Med Chem; 2016 Dec; 59(23):10642-10660. PubMed ID: 27809521
[TBL] [Abstract][Full Text] [Related]
5. Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole.
Zhang B; Ruan ZW; Luo D; Zhu Y; Ding T; Sui Q; Lei X
Mar Drugs; 2020 Jun; 18(7):. PubMed ID: 32629787
[TBL] [Abstract][Full Text] [Related]
6. Synthetic routes and biological evaluation of largazole and its analogues as potent histone deacetylase inhibitors.
Li S; Yao H; Xu J; Jiang S
Molecules; 2011 Jun; 16(6):4681-94. PubMed ID: 21654576
[TBL] [Abstract][Full Text] [Related]
7. Largazole: from discovery to broad-spectrum therapy.
Hong J; Luesch H
Nat Prod Rep; 2012 Apr; 29(4):449-56. PubMed ID: 22334030
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups.
Bhansali P; Hanigan CL; Perera L; Casero RA; Tillekeratne LM
Eur J Med Chem; 2014 Oct; 86():528-41. PubMed ID: 25203782
[TBL] [Abstract][Full Text] [Related]
9. Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
Reddy DN; Ballante F; Chuang T; Pirolli A; Marrocco B; Marshall GR
J Med Chem; 2016 Feb; 59(4):1613-33. PubMed ID: 26681404
[TBL] [Abstract][Full Text] [Related]
10. Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships.
Poli G; Di Fabio R; Ferrante L; Summa V; Botta M
ChemMedChem; 2017 Dec; 12(23):1917-1926. PubMed ID: 29117473
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of largazole zinc-binding group analogs.
Kim B; Ratnayake R; Lee H; Shi G; Zeller SL; Li C; Luesch H; Hong J
Bioorg Med Chem; 2017 Jun; 25(12):3077-3086. PubMed ID: 28416100
[TBL] [Abstract][Full Text] [Related]
12. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
Taori K; Liu Y; Paul VJ; Luesch H
Chembiochem; 2009 Jul; 10(10):1634-9. PubMed ID: 19514039
[TBL] [Abstract][Full Text] [Related]
14. Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole.
Clausen DJ; Smith WB; Haines BE; Wiest O; Bradner JE; Williams RM
Bioorg Med Chem; 2015 Aug; 23(15):5061-5074. PubMed ID: 26054247
[TBL] [Abstract][Full Text] [Related]
15. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
Ying Y; Taori K; Kim H; Hong J; Luesch H
J Am Chem Soc; 2008 Jul; 130(26):8455-9. PubMed ID: 18507379
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of class I HDAC isoform selectivity of largazole analogues.
Kim B; Park H; Salvador LA; Serrano PE; Kwan JC; Zeller SL; Chen QY; Ryu S; Liu Y; Byeon S; Luesch H; Hong J
Bioorg Med Chem Lett; 2014 Aug; 24(16):3728-31. PubMed ID: 25070421
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds.
Dewaker V; Srivastava PN; Verma S; Prabhakar YS
J Biomol Struct Dyn; 2020 Mar; 38(4):1197-1213. PubMed ID: 30909817
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs.
Guerra-Bubb JM; Bowers AA; Smith WB; Paranal R; Estiu G; Wiest O; Bradner JE; Williams RM
Bioorg Med Chem Lett; 2013 Nov; 23(21):6025-8. PubMed ID: 24035339
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.
Pilon JL; Clausen DJ; Hansen RJ; Lunghofer PJ; Charles B; Rose BJ; Thamm DH; Gustafson DL; Bradner JE; Williams RM
Cancer Chemother Pharmacol; 2015 Apr; 75(4):671-82. PubMed ID: 25616967
[TBL] [Abstract][Full Text] [Related]
20. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.
Bhansali P; Hanigan CL; Casero RA; Tillekeratne LM
J Med Chem; 2011 Nov; 54(21):7453-63. PubMed ID: 21936551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
